Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q1 2024 Earnings Presentation
27 slides from Avita Medical's earnings presentation, May 22, 2024
Slide 1: Investor Presentation Q1 2024
NASDAQ: RCEL ASX: AVH For personal use only Investor Presentation Q1 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements
Slide 3: Leadership
Leadership For personal use only Donna Shiroma Debbie Garner Jim Corbett David O’Toole SVP, Global Marketing & Chief Executive Officer* Chief Financial Officer* General Counsel* Strategy 30+ Years of Experience 30+ Years of Experience 20+ Years of Experience 20+ Years of Experience * Denotes executi
Slide 4: Investment Overview
Investment Overview > Commercial-stage company focused on regenerative medicine to transform the standard of care in wound care management and skin restoration with innovative technology For personal use only Current U.S. Products/Indications: > • RECELL: • Thermal burn wounds and full-thickness ski
Slide 5: RECELL Platform. Multiple Indications.
RECELL Platform. Multiple Indications. For personal use only Approved U.S. INDICATIONS 2022 2023 2024 2025 Outpatient Code Ease of Use Device BURNS Japan: Approval, RECELL GO Device Submission: June 30 Expect RECELL GO FDA Reimbursement, Launch Approval*: May 30 RECELL GO mini FDA Submission*: June
Slide 6: Technology Overview: RECELL
For personal use only Technology Overview: RECELL P6
Slide 7: What is RECELL?
What is RECELL? T R E AT M E N T US I N G R EC E L L R EC E L L enables For personal use only Deliver: autologous suspension sprayed regeneration of healthy onto treatment areas of patient skin 3 2 Prepare: at patient’s bedside, process skin and disaggregate cells with RECELL to produce regenerative
Slide 8: RECELL Device Evolution
RECELL Device Evolution For personal use only R EC E L L G O M U LT I - U S E P R O C ESS I N G D EV I C E ( R P D ) R EC E L L G O S I N G L E - U S E C A RT R I D G E ( R P K ) FIRST GENERATION DEVICE RECELL GO DEVICE • Fewer steps and streamlined • Simple user interface workflow, allowing for fas
Slide 9: Average Selling Price for RECELL GO
Average Selling Price for RECELL GO FDA APPROVED DEVICES For personal use only • 1920: $6,500 • RECELL Ease of Use: $6,500 PENDING FDA APPROVAL • RECELL GO: • Multi-use processing device: to provide at no cost • Single-use cartridge: $6,500 R EC E L L G O S I N G L E - U S E C A RT R I D G E R EC E
Slide 10: RECELL GO Manufacturing
RECELL GO Manufacturing For personal use only WE ARE READY • Top 28 burn accounts prioritized for conversion upon FDA approval • Ample inventory ready for immediate shipment • Sales team is trained and ready for the field P 10
Slide 11: Technology Overview: PermeaDerm
For personal use only Technology Overview: PermeaDerm P 11
Slide 12: What is PermeaDerm?
What is PermeaDerm? > N E XT- GE N E RAT I O N D R ESS I N G For personal use only • Temporary, biosynthetic wound matrix applied for the treatment and healing of a variety of wounds until healing is achieved > F DA- C L E AR E D • Partial-thickness wounds, donor sites, and coverage of meshed autogr
Slide 13: PermeaDerm Strategy
PermeaDerm Strategy On January 10, 2024, AVITA Medical signed distribution agreement with Stedical Scientific For personal use only to commercialize PermeaDerm ® Biosynthetic Wound Matrix MARKET • United States • Trauma centers and burn centers SALES FORCE • Same sales force as RECELL KEY TERMS • AV
Slide 14: Transforming into a Broad Wound Care Company
For personal use only Transforming into a Broad Wound Care Company P 14
Slide 15: Strategic Transformation – Continuum of Wound Care
Strategic Transformation – Continuum of Wound Care For personal use only Continuum of Burn/Full-Thickness Skin Defect Wound Care Dermal Wound Bed Replacement/ Epidermal Wound Bed Hemostasis Dressings Preparation Scaffolds/ Skin Replacement Substitutes RECELL stimulates Exploration Actively exploring
Slide 16: Product Compatibility for Wound Care
Product Compatibility for Wound Care Clinical Presentation: full-thickness skin defect with concern for infection For personal use only Dressing optimized for protection and moisture PermeaDerm by Stedical management RECELL + meshed split- Robust closure using significantly less skin thickness skin
Slide 17: Commercial Overview
For personal use only Commercial Overview P 17
Slide 18: RECELL: Market Sizing for Burn and Full-Thickness Skin Defects
RECELL: Market Sizing for Burn and Full-Thickness Skin Defects Market Size Additional Market Opportunity Prior to FDA Approval 1 with FDA Approved Expanded Indication of FTSD1 For personal use only Traumatic Wounds Traumatic Wounds Surgical Wounds • Degloving (Open Wounds) 99,000 • Gun Shot Wounds 1
Slide 19: Strong Pipeline as of May 10, 2024
Strong Pipeline as of May 10, 2024* For personal use only RECELL for Full-Thickness Skin Defects Value Analysis Committee (VAC) Submissions 178 Approvals Expected in Previously Announced Rejections Q2 New Accounts 46 73 8 Targeting 700+ Trauma & Burn Centers (next 2-3 years) * From the launch of the
Slide 20: Global Commercialization Strategy for RECELL
Global Commercialization Strategy for RECELL FOCUSED MARKET For personal use only • Australia • European Union • Japan STRATEGY • Plan to expand exclusively through third-party distribution partners UPDATE • In November 2023, engaged first European distribution partner, PolyMedics Innovations, to le
Slide 21: Long-term Horizon: Vitiligo Opportunity
Long-term Horizon: Vitiligo Opportunity > R EC E I V E D F DA A P P ROVA L I N J U N E 2023, W I T H ST U DY R E S U LTS : Patient from a prior study at six-months • Primary endpoint: proportion of study sites achieving ≥80% re- RECELL-treated area was 100% For personal use only pigmentation for REC
Slide 22: Financials
For personal use only Financials P 22
Slide 23: Financial Update
Financial Update Q 1 2024 F I N A N C I AL R ES U LTS For personal use only Commercial revenue, excluding BARDA revenue: • $11.1 million; increase of ~5.8% compared to same period in 2023 Gross profit margin: • 86.4% Cash and cash equivalents: • As of March 31, 2024: approximately $68.2 million 2024
Slide 24: Financial Overview
Financial Overview For personal use only Three-Months Three-Months Ended Full-Year Ended Ended (USD in $000s) Mar 31, 2023 Jun 30, 2023 Sep 30, 2023 Dec 31, 2023 2023 Mar 31, 2024 Commercial Sales $10,458 $11,686 $13,547 $14, 102 $49,775 $11,068 Total Revenue $10,550 $11,753 $13,645 $14,195 $50,143
Slide 25: Summary
For personal use only Summary P 25
Slide 26: Looking Ahead: 2024 Priorities
Looking Ahead: 2024 Priorities > SA L ES E X ECU T I O N • Expand into trauma centers with full-thickness skin defect indication by working through VAC approval For personal use only process; targeting at least 45 new accounts per quarter • Continue to penetrate, adopt, and grow in core burn centers
Slide 27: For personal use only
For personal use only